Introduction
Lung cancer is the leading cause of cancer-related deaths worldwide, accounting for approximately one-fourth of all cancer deaths [1] . It is divided into two major categories: non-small-cell lung cancer (NSCLC) and small-cell lung cancer. NSCLC is the most common type of lung cancer, accounting for almost 85% of all lung cancer. Adenocarcinoma and squamous cell carcinoma (SCC) are the most frequent histologic subtypes, making up 50 and 30% of NSCLC cases, respectively [2] .
The complexity of lung cancer makes its treatment difficult. Despite better techniques of surgery and improvement in adjuvant and neoadjuvant therapy for resectable lung cancer, the 5-year survival rate for lung cancer has only increased modestly from 10 to 15% [3] and the median survival of advanced NSCLC is only 8-10 months [4] . With the increased understanding of molecular alternations in lung cancer, recent research efforts have focused considerably on identifying molecular targets and using this knowledge to develop molecular-targeted therapies. The phosphatidylinositol-3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) signaling pathways are instrumental in regulating cellular metabolism, tumor development, growth, proliferation, metastasis, and cytoskeletal reorganization in tumors, which is frequently deregulated because of mutations affecting one of its upstream regulators, such as epidermal growth factor receptor (EGFR), or other components within the pathway in lung cancer [5] . It has been identified that genetic alternations, such as PIK3CA mutations, PTEN mutations/deletions, etc. within this pathway were not only to be known as driver mutations in lung cancer [6] but also to be known as the biomarkers of resistance to EGFR-tyrosine kinase inhibitors (TKIs), which have proved superior to chemotherapy for patients with EGFR-mutant NSCLC as the first-line treatment [7] . Therefore, a number of signaling nodes of this pathway have been targeted individually for lung cancer therapy. Inhibitors of these molecular targets have shown activity in NSCLC cell lines in vitro and in vivo, and some compounds as personalized therapy have entered early clinical trials [8] . This review mainly focuses on the mutations within the PI3K/AKT/mTOR pathway in NSCLC and the novel inhibitors that target these mutations in the current preclinical or early clinical study.
PI3K/AKT/mTOR pathway with cross-talk and a feedback loop
Some alternations in oncogenic receptor tyrosine kinases (RTKs) such as EGFR mutation or insulin growth factor receptor amplification can activate downstream PI3K at the membrane. PI3K are classified into three groups (classes I, II, and III), among which class IA, consisting of the regulatory subunit (p85) and the catalytic subunit (p110α encoded by PIK3CA, p110β encoded by PIK3CB, and p110ϐ encoded by PIK3CD), is the only type identified to have a common mutation in human cancers [9] . Subsequently, activated PI3K catalyzes the phosphatidylinositol-4,5-bisphosphate (PIP2) into phosphatidylinositol-3,4,5-triphosphate (PIP3), whereas PTEN directly opposes the activity of PI3K by dephosphorylating PIP3 into PIP2, thus acting as the central negative regulator of this pathway [10] . Afterwards, PIP3 recruits Akt and phosphoinositide-dependent protein kinase 1 (PDK1) to the cell membrane, where Akt is fully activated following phosphorylation by PDK1 and the rapamycin-insensitive mTOR complex (mTORC2) [11] . Activated Akt is released from the plasma membrane and phosphorylates multiple nuclear and cytoplasmic targets. These targets include the tuberous sclerosis complex 2 (TSC2), which results in TSC1/2 complex inhibition, and then the relief of inhibition of Rheb activity by the TSC1/2 complex. Subsequently, Rheb activates downstream mTORC1, which acts on substrates including p70 S6 kinase (S6K) and eIF4E-binding protein 1 (4E-BP1) to influence protein synthesis and tumorigenesis [12] . Furthermore, the TSC1/2 complex is also activated under nutrient/energy-poor conditions by serine/threonine protein kinase 11 (LKB1/STK11) and subsequent AMPactivated protein kinase (AMPK) [13] , which inhibits the function of Rheb and the downstream pathway (Fig. 1) .
Stimulation of RTKs also activates the Rat sarcoma (RAS)/rapidly accelerated fibrosarcoma (RAF)/mitogenactivated protein kinase (MEK)/extracellular signalregulated kinase (ERK) pathway, leading to upregulation of various transcription factors and the development of many cancers including NSCLC [14] . There is multiple cross-talk between PI3K/AKT/mTOR and RAS/ RAF/MEK/ERK pathways. For example, Ras generates PIP3 by directly activating PI3K [15] and ERK1/2 modulates mTOR through phosphorylation and inactivation of TSC2 and subsequent TSC1/2 inhibition in cancers [16] . In addition, the feedback loop in the PI3K/ AKT/mTOR pathway is significant in cancers. Studies have proved that S6K1 phosphorylation by mTORC1 directly phosphorylates insulin receptor substrate 1 (IRS-1), leading to a significant attenuation of the RTK effect and downstream PI3K/Akt activity or inhibition of the MEK/ERK signaling pathway by a mechanism that has not been fully understood as yet [17] (Fig. 1) . Therefore, because of complex machinations and interactions, the drug resistance or failure of monotherapy targeting only the PI3K/AKT/mTOR pathway is evitable and combination therapy with EGFR-TKI or RAS/ RAF/MEK/ERK inhibitors may overcome the resistance and improve outcomes for some patients.
Genetic alternations of the PI3K/AKT/mTOR pathway in NSCLC Phosphorylation of AKT is evident in 50-70% of NSCLC, indicating that activation of the PI3K/AKT/mTOR signaling pathway is a frequent event in such a malignancy [18] . Constitutive activation of this pathway may occur as a consequence of genetic changes in upstream signaling components (e.g. EGFR mutations, KRAS mutation), PTEN loss, or activation of downstream elements of the pathway (Table 1) .
EGFR TK domain mutations are statistically significantly more frequent in adenocarcinoma versus SCC (40 vs. 3%) in East Asian ethnicity versus other ethnicities (30 vs. 8%) [19, 20] . However, increased EGFR copy number in NSCLC is also more frequent in adenocarcinoma (41%), slightly higher than that in SCC (35%) [21, 22] . Anaplastic lymphoma kinase (ALK) translocation is detected in 3-6.7% of NSCLC [23, 24] and some studies show that ALK translocation mainly occurs in adenocarcinoma (5/149, 3.4%) rather than SCC (0%) [25] . Therefore, the EGFR-TKI (erlotinib and gefitinib) and ALK inhibitors (crizotinib) have significantly improved response rates and progression-free survival in lung adenocarcinoma, and not in SCC, which currently has no available alternative personal therapy to standard chemotherapy [7, 26] . Despite these benefits on adenocarcinoma, there exist innate resistance and acquired resistance to EGFR-TKIs therapy in patients with lung adenocarcinoma because of the downstream PI3K/AKT/mTOR activation or the KRAS mutation [7] . This suggests that EGFR-TKI in combination with the PI3K/Akt/mTOR pathway inhibitor according to genetic status of this pathway will be more effective in adenocarcinoma. The KRAS mutation occurs in 16-30% of NSCLC. It occurs more frequently in adenocarcinoma (10-30.6%) than in SCC (5-9%) [19, 22, [27] [28] [29] [30] . KRAS mutations are shown not to coexist with the EGFR mutation and are considered to be a dominant determinant of resistance to EGFR-TKIs and PI3K/AKT/mTOR inhibitors [19, 27, 31] .
LKB1 mutations differ in various ethnicities. Nearly half of the NSCLC cell lines in White patients, 17% of NSCLC tumors in the USA, and 2-10.5% of NSCLC tumors in East Asia including Korea, Japan, and China harbor LKB1 mutations. It occurs more commonly in adenocarcinoma than in SCC [30, [32] [33] [34] . Moreover, LKB1 mutations are frequently concurrent with the EGFR mutation and/or the KRAS mutation in NSCLC [30, 33, 34] .
Somatic activating mutations in the PIK3CA gene, which encodes the catalytic p110α subunit of PI3K, have been described to occur at a high frequency in various malignancies such as breast (27%), colorectal (15%), and endometrial (24%) cancers [18] . The common mutations are in the helical domain encoded by exon 9 (E542, E545) that interfere with p85α binding and in the kinase domain encoded by exon 20 (H1047R, H1047L) [35] . However, only 3.6-4% PIK3CA mutations occur in NSCLC [36] and the PIK3CA mutation is more frequent in SCC (3.9-6.6%) than in adenocarcinoma (1.5-2.7%) [37, 38] . Studies show that PIK3CA mutations frequently coexist with EGFR mutations and KRAS mutations, and patients with PIK3CA mutations have shorter overall survival than those with the PIK3CA-EGFR/KRAS comutation or wild-type PIK3CA [37, 38] . PIK3CA mutations have also been detected in about 5% of EGFR-mutant lung cancers with acquired resistance to EGFR-TKI therapy [39] . PIK3CA amplifications in the 3q locus are another mechanism of oncogenic activation, which are more frequent (18%) than mutations in NSCLC, being observed more frequently in SCC (33.1-37%) than in adenocarcinoma (5-6.2%) [40, 41] . Adenocarcinoma with PIK3CA amplification tends to have other gene mutations, suggesting that PIK3CA amplification may not be enough for the pathogenesis of adenocarcinoma, whereas PIK3CA amplifications are mostly present in SCC, indicating that PIK3CA amplification may play a pivotal role in the pathogenesis of SCC; therefore, targeting the PI3K/AKT/mTOR pathway activated by PIK3CA amplification or mutation is a potential therapeutic biomarker for SCC [41] . Preclinical studies have shown that resistance to PI3K inhibitors in PIK3CA-mutant tumors may be mediated by the presence of an activated RAS/RAF/MEK pathway [31] .
Mutations or loss of heterozygosity of PTEN are rare (< 6%), but considered to be potential driver mutations in NSCLC [6, [42] [43] [44] [45] . However, loss of PTEN protein expression occurs frequently, which represents a poor prognostic factor in NSCLC (41.4-74%) [44, 45, 46] , being reported more in SCC (59%) than in adenocarcinoma (34%) [45] . This may be attributed to promoter hypermethylation, which occurs in 26-35% of cases [44, 47] . Studies indicate that PTEN genetic status and loss of PTEN expression may be predictors for the sensitivity of PI3K/AKT/mTOR inhibitors [31, 48] .
The E17K mutation in the pleckstrin homology domain of the AKT1 gene is associated with increased membrane localization, which results in increased autophosphorylation of AKT1. This mutation appears to be frequent in breast, ovarian, and colorectal tumors [49] . However, it is present at a lower frequency in NSCLC (0-1.9%) and all reported NSCLC tumors harboring the AKT1 mutation have an SCC histology [50] . The subset of patients harboring the AKT1 E17K mutation may represent candidates for molecular targeting therapy and mediate the sensitivity to such inhibitors. In addition, although the AKT1 E17K mutation is rare, increased AKT signaling activated by upstream mediators is commonly observed, and AKT inhibitors have also been identified to target the activated AKT pathway [51] .
Novel inhibitors targeting the PI3K/AKT/mTOR pathway in NSCLC
The treatment of NSCLC has been revolutionized, switching from a 'one size fits all' approach to a personalized therapy. Because activation of the PI3K/ AKT/mTOR pathway plays a prominent role in regulating cell growth and survival in NSCLC, various inhibitors targeting the critical component in such a pathway have become an important advancement in NSCLC treatment (Table 2 ). However, because of the different genetic status in NSCLC and cross-talks or feedback loops in such pathways, monotherapy according to genetic status or combined therapy with other inhibitors may overcome the potential resistance and improve outcomes for patients.
PI3K inhibitors
PI3K inhibitors are classified into pan-PI3K inhibitors and isoform-selective PI3K inhibitors. The first generation of PI3K inhibitors such as wortmannin and LY294002 exerted potent anticancer effects in a preclinical study, but had limitations of lack of selectivity, poor solution, and instability that limited their clinical application. However, they promoted the development of novel targeted PI3K inhibitors [52] .
GDC-0941, an oral reversible pan inhibitor of class I PI3K, was sensitive to NSCLC cell lines harboring RTK activation, PIK3CA mutation, or amplification and PTEN loss [40] . It was reported to be more efficacious in gefitinib-resistance cells with a PIK3CA mutation than in gefitinib-resistance cells without a PIK3CA mutation [53] . GDC-0941 in combination with erlotinib or ERK pathway inhibitors exerts greater effects on cell viability than AKT1, protein kinase B1; ALK, anaplastic lymphoma kinase; EGFR, epidermal growth factor receptor; KRAS, K-ras sarcoma gene; mTOR, mammalian target of rapamycin; NSCLC, non-small-cell lung cancer; PIK3CA, phosphatidylinositol-3 kinase catalytic α; PTEN, phosphatase and tensin homolog deleted on chromosome 10. Table 2 Novel inhibitors targeting the PI3K/AKT/mTOR pathway in NSCLC Inhibitors of the PI3K/AKT/mTOR pathway in NSCLC Sun et al. 5
alone in NSCLC cell lines and xenografts [40, 53] SAR245408 (XL147) is a potent, orally bioavailable inhibitor of the class I PI3K family, binding in an ATPcompetitive and reversible manner. Oral administration of SAR245408 to mice bearing A549 lung adenocarcinoma cells (expressing activated KRAS and deficiency in LKB1) resulted in significant inhibition of the tumor PI3K pathway. It also led to significant tumor growth inhibition or tumor shrinkage in preclinical cancer models including lung cancer [61] . Phase I trials show that MTD in advanced solid tumors including NSCLC was 600 mg in both continuous and intermittent schedules, with DLTs including maculopapular rash and hypersensitivity reaction. SAR245408 inhibited the PI3K pathway (40-80% reduction in phosphorylation of AKT, PRAS40, 4E-BP1, and S6) and was more sensitive in patients with NSCLC with a PIK3CA mutation (E545 mutation) than those with wild-type PI3K. Unexpectedly, pERK1/2 was also reduced by XL147 in contrast with induction by mTORC1 inhibitors, which may suggest interference with other positive pathway cross-talk between PI3K and RAS pathways [62, 63] . Other trials of SAR245408 in combination with paclitaxel or erlotinib in prostate and breast cancers, respectively, indicate more potent inhibition than a single SAR245408 treatment [62] .
PX-866, an improved wortmannin analogue, is a pan-class 1A and B PI3K inhibitor. It has shown single-agent invivo antitumor activity and to increase the antitumor effects of cisplatin and radiation treatment [64] . It also potentiates the antitumor activity of gefitinib against NSCLC xenografts [65] . Mutant PI3K (PIK3CA) and loss of PTEN activity may be predictors of sensitivity to the antitumor activity of PX-866 in the presence of wild-type RAS, whereas mutant oncogenic RAS was a dominant determinant of resistance, even in tumors with coexisting mutations in PIK3CA [31] . A phase I trial of PX-866 indicated that the intermittent schedule MTD is 12 mg and the DLTs (16 mg) were diarrhea and ALT/AST elevation [66] .
SF1126, a novel RGDS-conjugated LY294002 prodrug, shows increased solubility and binds to specific integrins within the tumor compartment, resulting in enhanced antitumor and antiangiogenic activity [67] . Two phase I trials of SF1126 in solid tumors showed that only one common DLT was observed at the 180 mg/m 2 dose twice weekly, consisting of a G3 hypersensitivity reaction manifested by hypotension and also diarrhea. Significant inhibition of pS6 was observed in pancreatic cancer. Doses up to 630 mg/m 2 administered twice weekly did not lead to the MTD of SF1126 and dose escalation is ongoing in solid tumors [68, 69] . However, no present clinical trials of NSCLC are ongoing.
PIK-75, A66, and MLN-1117 (INK-1117) are isoformspecific p110α-selective inhibitors developed to potentially increase p110α inhibition and attenuate toxicities related to modulation of the other isoforms. These kinds of drugs have fewer side effects, and are sensitive in-vitro cell lines and in-vivo xenografts harboring a PIK3CA mutation, not harboring PIK3CA amplification and PTEN-null [70] [71] [72] . Torbett et al. [72] and Jamieson et al. [70] showed that activation of AKT was more sensitive to A66 and PIK-75 in H1047R mutation cells, but not in E545 mutation cells, which may be because of the different functions of these two main oncogenic forms of the p110α in vivo and in vitro. Iartchouk et al. [71] indicated that all models with PTEN alterations were found to be insensitive to MLN-1117 in vitro, whereas several of these models were found to have borderline sensitivity in vivo.
GDC-0032 is a potent and selective inhibitor of class I PI3K α γ ϐ isoforms. Preclinical data showed that GDC-0032 enhanced activity against PIK3CA-mutant cancer cell lines [73] , and an ongoing phase I trial of GDC-0032 has been well tolerated, with an MTD of 16 mg daily during escalation, and the DLTs were G3 acute renal failure (12 mg), G4 hyperglycemia, and G3 fatigue (16 mg) [74] . GSK2636771 and AZD6482 have been identified to be potent and selective inhibitors of the p110β isoform for the treatment of PTEN-deficient tumors [75, 76] . However, a preclinical study showed that PTEN-mutant endometrioid endometrial cancer lines were resistant to GSK2636771 and AZD6482, and only in combination with A66 was a decrease in cell viability observed, which suggested that inhibition of p110β alone may not be sufficient to sensitize PTEN-mutant endometrioid endometrial cancer cells and combination with other targeted agents may be required [48, 77] .
AKT inhibitors
Although the E17K mutation of the AKT1 gene is rare in NSCLC, phosphorylation of AKT is evident in 50-70% of NSCLC [18] . In terms of predictive biomarkers, there appears to be a relationship between the presence of PIK3CA mutations or PTEN loss with sensitivity to AKT inhibitors [48, 78, 79] .
Perifosine, as an alkylphospholipid, exerts its antitumor effects mainly by targeting cell membrane, metabolism, and permeability [80] . The mechanism of its tumorinhibitory remains unclear. It has been shown that perifosine decreases pAKT and inhibits AKT activation by interfering with AKT translocation to the cell membrane through its pleckstrin homology domain, and some studies have shown its regulation on MAPK, JNK, DR5, and GSK3 in tumors including NSCLC [81, 82] . Dasmahapatra et al. [83] reported that perifosine at a concentration of 1.5 µmol did not affect the A549 cells significantly. However, 1.5 µmol of perifosine in combination with 40 nm of UCN-01 (PDK1 inhibitor) induced synergy in the inhibition of AKT activation and induction of apoptosis. It can be considered that UCN-01 and perifosine could each affect different steps in the loss of AKT activation, leading to full activation of AKT. Two phase I trials evaluating the escalation of perifosine showed that the common adverse events included nausea, diarrhea, and vomiting. No DLT was reached, but the side effects, gastrointestinal complaints, led to early discontinuation at a higher dose level, leading to the decision to stop further dose escalation of this inhibitor; therefore, the MTD was established at 200 mg/day and oral perifosine was tolerable up to 600 mg/week in cancer patients. A weekly regimen was recommended because of its half-life of about 4 days [84, 85] . Another phase I trial of combined treatment with perifosine and radiation in patients with advanced tumors including NSCLC showed that a dosage of 150 mg/day, to be started at least 1 week before radiotherapy, is recommended for phase II evaluation [86] . MK-2206 is an allosteric inhibitor with potent inhibition against all AKT forms, with more inhibition against AKT1 and AKT2 (IC 50 are 5 and 12 nmol/l, respectively) compared with AKT3 (IC 50 65 nmol/l) [87] . It exerts an antitumor effect by inactivating conformation of AKT, abrogation of AKT phosphorylation, and disruption of AKT membrane localization [88] . MK-2206 enhances the antitumor effect against cytotoxic agents (doxorubicin etc.), RTK inhibitors (cetuximab and erlotinib), and MEK Inhibitor (AZD6244) and induces their sensitivity in NSCLC cell lines [89] [90] [91] . Phase I trials of MK-2206 in advanced solid tumors showed that the MTD of MK-2206 was 60 mg and DLTs included skin rash and stomatitis [87, 92] . AZD5363, a novel pyrrolopyrimidine-derived compound, inhibits all AKT isoforms with potency of 10 nmol/l or less (pan-AKT inhibitor) and inactivates phosphorylation of AKT substrates in various cell lines. AZD5363 monotherapy inhibits the proliferation of 41 of 182 solid and hematologic tumor cell lines including NSCLC in vitro and exerts an antitumor effect in xenografts. The presence of PIK3CA and/or PTEN mutations may be a predictor of AZD5363 sensitivity, whereas RAS mutations may be predictors of AZD5363 resistance [48, 78] . Two phase I trials of AZD5363 in Western and Japanese patients with advanced solid tumors were conducted and the patients were treated in two schedules: continuous twice daily dosing (7/7) and an intermittent schedule twice daily dosing 4 days on 3 days off (4/7) [93] . In the Western study, the MTD for each schedule was 320 mg twice daily (7/7) and 480 mg twice daily intermittent dosing (4/7), whereas in the Japanese study, 320 mg twice daily (7/7) was not tolerated; the MTD for intermittent dosing (4/7) was 480 mg twice daily The most commonly reported adverse events were hyperglycemia, rash, and diarrhea. Partial responses were noted in patients with mutations driving the PI3K pathway such as the PIK3CA mutation and the AKT1 mutation.
Various other oral pan-AKT inhibitors, such as GDC-0068, GSK2110183, and GSK2141795, are in early clinical development. These agents block the phosphorylation of multiple downstream targets of Akt and have more potent activity against cancers with the E17K AKT1 mutation in contrast to AKT allosteric inhibitors in advanced solid tumors [35, 79, 94, 95] . Lin et al. [79] reported that markers of Akt activation, including highbasal pAKT levels, PTEN loss, and PIK3CA kinase domain mutations, correlated with sensitivity to GDC-0068.
mTOR inhibitors
Rapamycin, developed initially as an antifungal drug, also possesses immunosuppressive and anti-proliferative properties, which was analyzed against a panel of human cancer cell lines and was found to have broad anticancer activity [96] . Rapamycin was also efficacious in inhibiting the growth of NSCLC cells and in animal models [97] . However, clinical development of rapamycin as anti-cancer agents was less than successful because of unfavorable pharmacokinetic properties [98] . Thus, few clinical data were available with rapamycin for the treatment of NSCLC. The rapamycin analogues were developed to have a more favorable pharmacokinetic profile than rapamycin, which led to the evaluation of mTOR inhibitors as anticancer agents. Currently, the rapamycin analogues include temsirolimus (CCI779), everolimus (RAD001), and rifaforolimus (AP23573, MK-8699), which are similar to rapamycin in that they affect only mTORC1, but not mTORC2 [99] . We have mentioned above that mTOR downstream S6K1 shows a feedback loop involving suppression of the Akt or the ERK pathway; therefore, these mTORC1 inhibitors would potentially activate the Akt or the ERK pathway as a compensatory mechanism, which may lead to drug resistance or even disease progression and toxicity in tumors. For this reason, the clinical utility is limited and their combination with PI3K inhibitors or MEK inhibitors may have a broader targeting range and enhance anticancer sensitivity.
Temsirolimus (CCI779) has been approved by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMEA) for the treatment of advanced renal cell carcinoma (RCC). In preclinical studies, temsirolimus was shown to inhibit mTOR phosphorylation and suppress the proliferation of NSCLC cell lines, as well as inducing a potent antitumor effect in NSCLC xenografts [100] . A clinical trial of temsirolimus showed that a patient with NSCLC achieved a confirmed partial response, lasting for 12.7 months [101] . The MTD was 15 mg/m 2 /day and the DLTs were G3 vomiting, diarrhea, and G3 elevated transaminases (at 19 mg/m 2 /day) [101, 102] . However, in a recent phase II trial, temsirolimus 25 mg was administered weekly on a 4-week cycle in 55 NSCLC patients and the dose was tolerated. The clinical benefit rate was 35%, with four patients achieving a confirmed partial response and 14 patients with stable disease for 8 weeks or more. The main adverse events (grade 3/4) occurring in 33 patients included dyspnea (12%), fatigue (10%), hyperglycemia (8%), hypoxia (8%), nausea (8%), and rash/desquamation (6%) [103] . Everolimus (RAD001) is another drug approved for the treatment of RCC. In preclinical studies, it restored the sensitivity of EGFR-TKI in resistant NSCLC cell lines [104] . The combination of everolimus and PI3K inhibitors exerts synergistic anticancer activity against NSCLC cancer in vitro and in vivo [58] . A clinical trial in solid tumors showed that the MTD was 10 mg/days or 50 mg/ weeks and the DLTs included G3 stomatitis, G3 neutropenia, and G3 hyperglycemia [105] . Single everolimus at 10 mg/day had modest clinical activity in pretreated NSCLC [106] . A recent phase II trial of everlimus (5 mg/ day)-erlotinib (150 mg) (n = 66) or erlotinib (150 mg) alone (n = 67) was conducted in NSCLC. The disease control rate at 3 months was 39.4 and 28.4%, respectively, which was below the prespecified probability threshold. The median progression-free survival was 2.9 and 2.0 months, respectively, which restricted further combination on the basis of increased toxicity and the lack of considerable improvement in disease stabilization [107] . Both phase I trials of everlimus with carboplatin and paclitaxel in advanced NSCLC naive to systemic therapy and phase II trials of everlimus and docetaxel in advanced-stage NSCLC treated with one or two previous systemic therapy regimens showed that the efficacy was relatively modest in an unselected population of patients with NSCLC [108, 109] . In another phase II trial of gefitinib and everlimus in stage IIIB/IV NSCLC with no previous chemotherapy and treated previously with cisplatin or carboplatin and docetaxel or pemetrexed, partial responses were observed in eight of 62 patients (response rate 13%). Among the responders, five had received no previous chemotherapy and three partial responders had an EGFR mutation. Both patients with a KRAS (G12F) mutation and 8% of patients with a non-EGFR mutant responded [110] . All the above trials indicate that everlimus in combination with other agents in the treatment of unselected NSCLC patients is less efficacious, and perhaps further investigation in combination therapy in selected patients such as those with a KRAS (G12F) mutation will be more promising.
Ridaforolimus (AP23573, MK-8699) elicits dosedependent inhibition of mTOR activity, with concomitant effects on cell growth and division in various tumor cell lines including NSCLC in vitro and robust antitumor activity in NSCLC xenografts. Neither PTEN nor pAKT is predictive for ridaforolimus responsiveness in various cancer cell lines [111] . It was shown that KRAS may be an important predictor because ridaforolimus inhibited NSCLC cell lines harboring KRAS mutations and also inhibited the growth of erlotinib-resistant, KRAS-mutant NSCLC xenograft models [112] . Phase I trials of ridaforolimus in advanced solid tumors including NSCLC showed that the MTD was 18.75 mg/days for 5 consecutive days every 2 weeks and one NSCLC experienced confirmed partial responses [113] , whereas Hartford et al. [114] reported that the MTD was 75 mg once weekly, with one patient having a partial response and 21 patients having stable disease. The common DLT was mucositis. Further clinical evaluations are necessary to study ridaforolimus; however, no current trials in NSCLC are ongoing.
In the last few years, a number of novel potent ATPcompetitive mTOR inhibitors (pan-mTOR) have been reported, which can inhibit both mTORC1 and mTORC2. They can inhibit the phosphorylation of mTORC1 substrates p70 S6K and 4E-BP1 as well as phosphorylation of the mTORC2 substrate AKT, thus reducing Akt reactivation by an S6K1 feedback loop and had a more complete anticancer activity compared with rapamycin analogues [115] . However, such inhibitors cannot inhibit MEK pathway activation by an S6K1 feedback loop; thus, these agents may be more efficacious in combination with other targeting drugs [116, 117] . These pan-mTOR inhibitors mainly include AZD8055, OSI-027, and INK128 (MLN0128).
AZD8055 potently inhibits proliferation and induces autophagy in NSCLC cell lines in vitro (H838 and A549) and leads to significant growth inhibition and or regression in NSCLC xenografts [118] . The combination of AZD8055 and an MEK inhibitor (selumetinib or AZD6244) synergistically inhibits rhabdomyosarcoma cell growth in vitro and tumor growth suppression in vivo in NSCLC [116, 117] . The MTD in two phase I trials of AZD8055 in advanced solid tumors in Western countries and Japan was 90 mg twice a day. The common DLTs were G3 increases in transaminases, reversible in all patients, with frequent adverse events being increased alanine aminotransferase, increased aspartate aminotransferase, and fatigue [119, 120] . OSI-027 and INK128 inhibit cell proliferation in various breast cancer cell lines harboring PIK3CA, PTEN loss, KRAS, and/or BRAF mutations in vitro, and decrease primary tumor growth in breast xenografts [115, 121] . INK128 also enhances the radiosensitivity of pancreatic carcinoma cells [122] . In a phase I trial of OSI-027, three DLTs were observed: one patient with G2 decreased left ventricular ejection fraction and two patients with G3 fatigue. Other drug-related toxicities included G3 nausea and vomiting, G3 pneumonia; G1/2 fatigue, nausea, diarrhea, anorexia, and elevated creatinine [123] . In addition, some other novel panmTOR inhibitors such as WYE-132, Torin1, and Torin2 are in preclinical studies [124, 125] .
Dual PI3K/mTOR inhibitors
The mTOR shares high sequence homology in the hinge region with PI3K; therefore, some novel inhibitors are identified as dual PI3K/mTOR inhibitors that inactivate both PI3K and mTORC1/2, reducing Akt activation by feedback loops and leading to a more complete suppression of the signaling pathway compared with mTOR inhibitors [126] . In addition, dual PI3K/mTOR inhibitors are better than a combination of PI3K inhibitors and mTOR inhibitors, resulting in fewer side effects and alleviation of activation of the ERK pathway by feedback loops [127] .
BEZ235, a dual PI3K/mTOR inhibitor, has been found to reduce pAkt and pS6 expression and to inhibit tumor cell growth, while enhancing the effects of cisplatin in NSCLC cell lines [128] . In xenografts, BEZ235 is sensitive to NSCLC with PIK3CA mutations, whereas it is resistant in a mouse lung cancer model driven by a KRAS mutation. The combination of BEZ235 and MEK inhibitors may overcome this resistance caused by a KRAS mutation [129] . However, Konstantinidou et al. [130] reported that although BEZ235 was not sufficient to induce apoptosis in NSCLC xenografts with oncogenic KRAS, it effectively sensitized these xenografts to the proapoptotic effects of ionizing radiation both in vitro and in vivo. Interestingly, although BEZ235 inhibits both PI3K and mTOR, the combination of mTOR inhibitors (rapamycin or everlimus) and BEZ235 leads to synergistic inhibition of the growth of human lung cancer cells and of the growth of lung cancer xenografts in mice [57, [127] [128] [129] [130] [131] . A multicenter, open-label, and doseescalation phase I study in 59 advanced solid tumors showed two partial responses (one Cowden syndrome and one breast cancer), 16 minor responses, and stable disease in 14 patients. There was no DLT and the most frequent adverse events were nausea, vomiting, diarrhea, fatigue/asthenia, anemia, and anorexia [132] .
GDC-0980, as a potent bioavailable dual PI3K/mTOR inhibitor with excellent pharmacokinetic and pharmaceutical properties, produces strong inhibition of a broad panel of cancer cell lines including lung cancers with PI3K activation and PTEN loss, and of tumor growth in NSCLC xenografts with activated PI3K, loss of LKB1, or PTEN [133] . Spoerke et al. [40] showed that GDC-0980 exerted some inhibition in NSCLC cell lines with KRAS and BRAF alternations compared with GDC-0941 resistance, and GDC-0980 showed greater antitumor activity than GDC-0941 in SCC models harboring KRAS mutations or dual PI3CA/KRAS mutations. Treatment of GDC-0941 and GDC-0980 resulted in increased expression of RTKs such as ERBB3 and MET as well as other pathway-related genes such as phosphoinositide-3-kinase interacting protein 1 (PIK3IP1) by feedback upregulation in response to PI3K inhibition. This phenomenon occurred to a greater extent in cell lines that are sensitive to PI3K inhibition, suggesting that cotargeting the EGFR or the MEK pathway may synergize in inhibition of cell growth. A phase I trial of GDC-0980 in advanced solid tumors indicated that no drug-related G3 or other adverse events or DLTs were observed with the tolerate dose at 16 mg/day. The most frequent adverse events were nausea (25%), fatigue (50%), diarrhea (42%), and flatulence (25%). Potential antitumor activity was observed in a mesothelioma and a soft tissue sarcoma [134] . XL765 (SAR245409), another dual PI3K/mTOR inhibitor, potently inhibits growth or causes tumor shrinkage in various xenografts including lung cancer. It is also shown to inhibit tumor cell proliferation and angiogenesis and induces apoptosis in NSCLC xenografts [135] . A recent phase I trial of XL765 evaluating safety and pharmacological properties in advanced solid tumors showed a reduction in PI3K and mTORC1/2 pathway signaling in serial hair sheath cells, skin, and tumor samples, with 48% stable disease (the best response reported) and 8% (7/83) minor tumor regression. The MTD was 50 mg twice daily and 90 mg daily. The most frequent adverse events were nausea (36.1%), diarrhea (21.7%), vomiting (19.3%), and decreased appetite (16.9%), with a frequent G3/4 increase in alanine aminotransferase (6.0%) and aspartate aminotransferase (4.8%). There were no correlations between tumor molecular alteration and antitumor activity [136] . Another trial of XL765 in combination with erlotinib in patients with 46 advanced solid tumors including 37 patients with lung cancers who had received an EGFR inhibitor once before entry showed that stable disease (the best response) occurred in 12 of 32 (37.5%) evaluable patients. The MTDs of XL765, in combination with erlotinib 100 mg daily, were 70 mg daily and 20 mg twice daily. The most frequent treatment-related adverse events (any grade) were diarrhea (35%), rash (35%), and nausea (28%), with no adverse events at grade 3/4 in more than one (2.2%) patient, and no major pharmacokinetic interaction between XL765 and erlotinib was noted [137] . Further clinical trials are required for XL765, but no present trials are ongoing.
PF-04691502, an ATP-competitive dual PI3K/mTOR inhibitor, was shown to reduce the phosphorylation of AKT T308 and AKT S473 (IC 50 7.5-47 and 3.8-20 nmol/l, respectively) and inhibit cell proliferation (IC 50 79-313 nomol/l) in PIK3CA-mutant and PTEN-deleted cancer cell lines including NSCLC. Antitumor activity was observed in gefitinib-resistant and erlotinib-resistant NSCLC xenografts, U87 (PTEN-null) and SKOV3 (PIK3CA mutation) [138] . The combination of PF-04691502 and MEK inhibitor (PD-0325901 at sub-MTD) significantly suppresses the growth of lung adenocarcinoma tumors in KRAS-G12D-LSL xenografts [139] .
Both PKI-587 (PF-05212384) and GSK2126458 have been identified to be dual PI3K/mTOR inhibitors. It was shown that PKI-587 induced apoptosis in human tumor cell lines including NSCLC with elevated PI3K/mTOR signaling, especially by PIK3CA mutant (E545K), and inhibited tumor growth in lung (H1975) xenograft models. Similarly, PKI-587 or GSK2126458 in combination with MEK inhibitors (PD-0325901 or GSK1120212) may enhance the overall efficacy and overcome acquired resistance to the BRAF Inhibitor mediated by N-rat sarcoma gene (NRAS) or MEK mutations [140, 141] . Some other novel dual PI3K/mTOR inhibitors such as BGT226 and BAY806946 are in preclinical studies showing increasing inhibitory activity against tumors [142, 143] . A phase I trial of BGT226 indicated that 30% (17/57) of patients showed stable disease as the best response. The MTD was 125 mg/day three times a week and the DLT in three patients were G3 nausea/vomiting and diarrhea, with adverse events including nausea (68%), diarrhea (61%), vomiting (49%), and fatigue (19%) [144] . Further preclinical and clinical trials of BGT226 or BAY806946 are required to study the related properties and function in tumors including NSCLC.
Conclusion and perspective
Over the past few years, considerable advances have been made in the targeted therapy against the PI3K/AKT/mTOR pathway in NSCLC. Most of them have entered clinical trials or have even been approved in RCC, with primary clinical data on NSCLC treatment.
Because of the development of genomic analyses, many genomic alternations of the PI3K/AKT/mTOR pathway or other pathways occurring in NSCLC have been well described, which may be considered biomarkers sensitive or resistant to novel inhibitors to enable optimal patient selection in future trials. Therefore, it is important that patients harboring specific molecular abnormalities such as PIK3CA alternations or AKT mutations or loss of PTEN or LKB1 are enrolled in clinical trials to improve the efficacy of novel inhibitors against NSCLC, although it is necessary to combine novel inhibitors with other targeted inhibitors, such as EGFR-TKI or ERK pathway inhibitors, to overcome the potential resistance and enhance the efficacy against NSCLC with KRAS mutations, EGFR mutations, or BRAF mutations.
In addition, because there is a significant negative feedback loop where S6K1 phosphorylation by mTORC1 directly phosphorylates IRS-1, leading to a significant attenuation of RTK effect and downstream PI3K/AKT activity or inhibition of the ERK signaling pathway, obvious compensatory feedback upregulation of RTKs or other pathways, such as the ERK pathway, is often observed, which limits the activity and effectiveness of these novel inhibitors. For this reason, the combination of agents targeting these signaling mechanisms at multiple levels will be required to fully overcome these feedback loops and improve the potential of PI3K/AKT/mTOR inhibitors.
In conclusion, personalized therapy with PI3K/AKT/ mTOR inhibitors has been proven to be promising therapeutic strategies to treat NSCLC. Understanding the importance of genetic alternations and the interconnected signaling network is required to develop more effective clinical strategies to maximize the antitumor efficacy in NSCLC.
